Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report deliverables include a PowerPoint report and an Excel-based forecast model and covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. This report also includes a number of recent enhancement to the forecast models, specifically the US LoA analysis tab and the interactive patient flow tab. The patient flow tab helps to summarize the number of patients treated on each class of therapy for each year of the forecast period for the 7MM.

GlobalData estimates the alopecia areata (AA) market to grow from $398.9 million in 2023 to $3.0 billion by 2033 at a compound annual growth rate (CAGR) of 22.7%. There will be an overall increase in the treated cases of AA in the seven major markets (7MM) (the US, France, Germany, Italy, Spain, the UK, and Japan) across the forecast period. JAK inhibitors are the only approved treatment option for AA, with on-label use for severe cases. Off-label treatment options for all severity levels include corticosteroids, immunomodulators, and immunotherapy. The alopecia areata pipeline in the 7MM draws an encouraging outlook for future therapies within this space, which include assets with varying mechanisms of action (MoAs). Among MoAs observed from late-stage pipeline agents is a JAK inhibitor (AbbVie’s upadacitinib) and an interleukin (IL)-2 T regulatory cell stimulator (Nektar Therapeutics’ Rezpeg). Among early-stage pipeline agents, a broader set of MoAs can be observed including interleukin-receptor agonists/antagonists, anti-OX40L monoclonal antibodies (mAbs), and stem cell therapy.

Scope

Overview of Alopecia Areata (AA) – including epidemiology, disease etiology and management.​

Topline AA drugs market revenue, annual cost of therapy, and anticipated sales for late-stage pipeline drugs.​

Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period.​

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.​

Analysis of the current and future market competition in the seven-market AA therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.​

Develop business strategies by understanding the trends shaping and driving the seven-market alopecia areata (AA) therapeutics market.​

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AA market in the future.​

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.​

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.​

Track drug sales in the seven-market AA therapeutics market from 2023-2033.​

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.​

AbbVie
Aclaris Therapeutics Inc
Amgen Inc
Concert Pharmaceuticals Inc
Eli Lilly and Co
Halo Pharma
Horizon Therapeutics USA Inc
Inmagene Biopharmaceuticals Ltd
Invyte Corp
Nektar Therapeutics
OMERS Life Sciences
Pfizer
Q32 Bio Inc
Regeneron GmbH
Sanofi
Sun Pharmaceuticals Industries Inc

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Alopecia Areata

3.2. Etiology and Pathophysiology of Alopecia Areata

3.3. Classification of Alopecia Areata

3.4. Alopecia Areata SWOT Analysis

4. Epidemiology

4.1. Diagnosed Incident Cases of AA, Men and Women, All Ages, 2023‒2033

4.2. Lifetime Diagnosed Prevalent Cases of AA, Men and Women, All Ages, 2023‒2033

4.3. 12‒Month Diagnosed Prevalent Cases of AA, Men and Women, All Ages, 2023‒2033

4.4. Age-Specific Diagnosed Incident Cases of AA, Men and Women, All Ages, 2023

4.5. Age-Specific Lifetime Diagnosed Prevalent Cases of AA, Men and Women, All Ages, 2023

4.6. Age-Specific 12-Month Diagnosed Prevalent Cases of AA, Men and Women, All Ages, 2023

4.7. Sex-Specific Diagnosed Incident Cases of AA, Men and Women, All Ages, 2023

4.8. Sex-Specific Lifetime Diagnosed Prevalent Cases of AA, Men and Women, All Ages, 2023

4.9. Diagnosed Incident Cases of AA by Severity, Men and Women, All Ages, 2023

4.10. Lifetime Diagnosed Prevalent Cases of AA by Severity, Men and Women, All Ages, 2023

4.11. 12-Month Diagnosed Prevalent Cases of AA by Severity, Men and Women, All Ages, 2023

4.12. Sources Used to Forecast the Diagnosed Incident Cases of AA

4.13. Sources Used to Forecast the Lifetime Diagnosed Prevalent Cases of AA

4.14. Sources Used to Forecast the 12‒Month Diagnosed Prevalent Cases of AA

4.15. Sources Used to Forecast the Diagnosed Incident Cases, Lifetime Diagnosed Prevalent Cases, and 12‒Month Diagnosed Prevalent Cases of AA by Severity

4.16. Sources and Methodology – Diagnosed Incident Cases of AA

4.17. Sources and Methodology – Lifetime Diagnosed Prevalent Cases of AA

4.18. Sources and Methodology – 12-Month Diagnosed Prevalent Cases of AA

4.19. Sources and Methodology – Diagnosed Incident Cases, Lifetime Diagnosed Prevalent Cases, and 12-Month Diagnosed Prevalent Cases of AA by Severity

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Topical Corticosteroid

5.4. Product Profile: Intralesional Corticosteroid

5.5. Product Profile: Systemic Corticosteroid

5.6. Product Profile: Vasodilator (Minoxidil)

5.7. Product Profile: Anti-Inflammatory/Immunotherapy (Anthralin)

5.8. Product Profile: Topical Immunotherapy (DNCB/DPCP/SADBE)

5.9. Product Profile: Immunomodulator (Azathioprine)

5.10. Product Profile: Immunomodulator (Cyclosporine)

5.11. Product Profile: Immunomodulator (Methotrexate)

5.12. Product Profile: JAK Inhibitor (Olumiant)

5.13. Product Profile: JAK Inhibitor (Litfulo)

5.14. Product Profile: JAK Inhibitor (Leqselvi)

6. Patient Flow

6.1. Patient Flow: Alopecia Areata in 2023 Across the 7MM (Pediatrics)

6.2. Patient Flow: Alopecia Areata in 2023 Across the 7MM (Adolescents)

6.3. Patient Flow: Alopecia Areata in 2023 Across the 7MM (Adults)

7. Unmet Needs and Opportunities

7.1. Unmet Needs in Alopecia Areata

7.2. Therapies with Higher Efficacy Profiles and New Mechanisms of Action

7.3. Lack of Cost-Effective Therapies

7.4. Up-to-Date Treatment Guidelines

7.5. Delay in Referrals to Dermatologists

8. R&D Strategies

8.1. Trends in Clinical Trials Design and New Mechanisms of Action

8.2. Trends in Deal-Making in Alopecia Areata

9. Pipeline Assessment

9.1. Alopecia Areata Pipeline Overview

9.2. Late-Stage Pipeline Agents for Alopecia Areata

9.3. Product Profile: AbbVie’s Upadacitinib

9.4. Product Profile: Nektar Therapeutics’ Rezpegaldesleukin

9.5. Alopecia Areata: Clinical Trials (Phase II/III) Overview

10. Market Outlook

10.1. Alopecia Areata Market Forecast

10.2. Market Drivers and Barriers

11. Appendix

11.1. Primary Research: KOL Information

11.2. Bibliography

11.3. About the Authors

12. Contact Us

Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Q1 2026 CRO Activity and Intel Report
$1,870 | May 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, April 2026
$2,950 | May 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 in real time.

  • Access a live Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.